Dermatology Collaboration and Licensing Deals 2016-2026

Key Benefits

✔ Benchmark against 506 dermatology partnering deals – Access real-world collaboration and licensing activity to identify relevant precedents and comparable transactions.

✔ Benchmark dermatology deal financials – Analyze disclosed headline values, upfront payments, milestones and royalty rates and investigate the individual transactions behind the benchmarks.

✔ Identify prospective partners and leading dealmakers – Discover companies with demonstrated interest in dermatology assets, technologies, therapeutic indications and relevant stages of development.

✔ Compare activity across the dermatology landscape – Analyze dealmaking by therapeutic indication, development stage, technology type, deal type, industry sector and company.

✔ Find the most relevant comparable transactions – Move beyond broad averages to identify deals involving similar indications, technologies, development stages and partnering structures.

✔ Understand how dermatology deals are structured – Examine licensing rights, development responsibilities, exclusivity, IP, commercialization rights, milestones, royalties and other important transaction provisions.

✔ Learn from real contract documents – Where publicly available, review underlying agreements to understand how rights, obligations, financial terms and other negotiated provisions have been documented.

✔ Apply the intelligence to your own dermatology opportunity – Qualifying customers may also be eligible for a Customized Executive Partnering Briefing focused on their own asset, indication, technology, prospective partners or transaction objectives.

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in dermatology dealmaking

 

2.1. Introduction

2.2. Dermatology partnering over the years     

2.3. Dermatology partnering by deal type

2.4. Dermatology partnering by industry sector

2.5. Dermatology partnering by stage of development

2.6. Dermatology partnering by technology type

2.7. Dermatology partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for dermatology partnering

 

3.1. Introduction

3.2. Disclosed financials terms for dermatology partnering

3.3. Dermatology partnering headline values

3.4. Dermatology deal upfront payments

3.5. Dermatology deal milestone payments

3.6. Dermatology royalty rates

 

Chapter 4 – Leading dermatology deals and dealmakers

 

4.1. Introduction

4.2. Most active in dermatology partnering

4.3. List of most active dealmakers in dermatology    

4.4. Top dermatology deals by value

 

Chapter 5 – Dermatology contract document directory

                                            

5.1. Introduction

5.2. Dermatology partnering deals where contract document available

 

Chapter 6 – Dermatology dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by dermatology therapeutic target

 

Deal directory

 

Deal directory – Dermatology deals by company A-Z

Deal directory – Dermatology deals by technology type

 

Deal type definitions

 

About Biopharma Research Ltd

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Dermatology partnering since 2016

Figure 2: Dermatology partnering by deal type since 2016

Figure 3: Dermatology partnering by industry sector since 2016

Figure 4: Dermatology partnering by stage of development since 2016

Figure 5: Dermatology partnering by technology type since 2016

Figure 6: Dermatology partnering by indication since 2016

Figure 7: Dermatology deals with a headline value

Figure 8: Dermatology deals with upfront payment values

Figure 9: Dermatology deals with milestone payment

Figure 10: Dermatology deals with royalty rates

Figure 11: Active dermatology dealmaking activity since 2016

Figure 12: Top dermatology deals by value since 2016

 

Pricing options

• $3,995: single-user (encrypted file - one user/device)
• $5,995: multi-user (encrypted file - up to 5 users/devices)
• $7,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

3Derm Systems, 3M, 23andMe, Abbvie, Abex Pharmaceutica, Ablexis, AbSci, Accro Bioscience, Aclaris Therapeutics, Adalvo, Adaptive Phage Therapeutics, Adhesys Medical, Advanced Human Imaging, Advanced Medical Solutions, Advanz Pharma, Advonex, AFT Pharmaceuticals, AiCuris, AimedBio, Akaal Pharma, Aldena Therapeutics, Alibaba Health, AlivaMab Discovery Services, Allergan, Allergan Aesthetics, Almirall, Alumis, Alvotech, American Skin Association, Amgen, Amicus Therapeutics, Amor (Suzhou) Medical Sci-Tech, Amyris, Amytrx Therapeutics, ANANDA Scientific, AnaptysBio, AnGes MG, Anhalt University of Applied Sciences, Animal Allergy Clinical Laboratories, Antibe Therapeutics, AOBiome Therapeutics, Aphex BioCleanse Systems, Applied Biology, APR Applied Pharma Research, Aquavit Pharmaceuticals, Arch Biopartners, Arctic Therapeutics, Arcutis Biotherapeutics, argenx, Armis Biopharma, Arrevus, Arrien Pharmaceuticals, Aslan Pharma, Aspire Pharma, AstraZeneca, Astria Therapeutics, Athenex, Atropos Therapeutics, Aucta Pharmaceuticals, Aurealis Therapeutics, Avaria Health & Beauty, Avicanna, AVIR Pharma, Avita Medical MENA, Avita Therapeutics, Azitra, Back-A-Line, BASF, Basilea Pharmaceutica, Bausch & Lomb, Bayer, Beckman Research Institute of City of Hope, Beiersdorf, Belle.ai, Ben-Gurion University, BGN Technologies, Bill and Melinda Gates Foundation, BinnoPharm, Bio-Gate, Bio-Thera Solutions, Biocogent, Biocon, BioCryst Pharmaceuticals, BioDerm, Biofrontera Pharma, Biogen, Biohaven Pharmaceuticals, BioLab Sciences, Biolojic Design, Biomedical Advanced Research and Development Authority, BIOMEDX Group, BioMed X Innovation Center, Biomillenia, BiomX, BiondVax, BioNexus Gene Lab, Bioniz Therapeutics, Bionpharma, BioPep, Biophage Pharma, BiopharmX, Bioqube Ventures, BiosanaPharma, Biosion, Biosolution, BioStem Technologies, BirchBioMed, Bodor Laboratories, Boehringer Ingelheim, Boragen, Bora Pharmaceuticals, Boston Pharmaceuticals, Botanix Pharmaceuticals, BoyaLife, Brickell Biotech, Brigham and Women's Hospital, Bright Future Pharmaceutical Lab, Bristol-Myers Squibb, Brown University, Cadila Pharmaceuticals, Camargo Pharmaceutical Services, Can-Fite BioPharma, Candela, CannaSkin, Cannassure Therapeutics, CanniMed Therapeutics, Canopy Growth, Cap Alter Pharma, Capital Laser and Skin Care, Cara Therapeutics, CARB-X, Cardiome Pharma, Carestream Health, Cassiopea, Castle Biosciences, Celgene, CellMark Medical, Cell Mogrify, Celularity, Certara, Ceva Sante Animale, Charles River Laboratories, Chelexa Biosciences, Chemstar, Children's Hospital Boston, China Medical System, Chongqing Jingdong Pharmaceutical, Chugai Pharmaceutical, Cipher Pharmaceuticals, Cipla, City of Hope, CIVCO Radiotherapy, CMS Aesthetics, CMS Medical, Codex Beauty, Collplant, Columbia University Medical Center, ConvaTec, Cook Biotech, Cosmofix, Cosmo Pharmaceuticals, Covalon Technologies, CR Double-Crane, Crescita Therapeutics, Cronos Group, Crown Laboratories, Cumberland Pharmaceuticals, CURE Pharmaceutical, Cutanea Life Sciences, Cutia Therapeutics, Cynata Therapeutics, Cytori Therapeutics, CytoSorbents, Dabur, Dalhousie University, DASH Analytics, Dechra Pharmaceuticals, Defense Health Agency (US), Defense Threat Reduction Agency, Denali Therapeutics, Department of Defense, Department of Veterans Affairs, Dermala, DermapenWorld, Dermata Therapeutics, Dermavant Sciences, Dermelix Biotherapeutics, Dermira, DermTech, Devonian Health Group, DKSH, Dong-A ST, Dow Pharmaceutical Sciences, Dr. Denese SkinScience, Dr. Reddy's Laboratories, Dr. U Devices, Draper Laboratories, Dr Bragi Company, Dr Kerklaan Therapeutics, DS Biopharma, Dyamed Biotech, Dynasil, EB Research Foundation, EB Research Partnership, Edesa Biotech, Egis, Eirion Therapeutics, Eisai, eKare, Elektrofi, Elevai Labs, Eligo Bioscience, Eli Lilly, Eloxx Pharmaceuticals, Emmaus Life Sciences, Empa, Emphysys, Encore Dermatology, Endo International, Enteris Biopharma, Enzymatica, Epicore Biosystems, EPI Health, epitoMAP, Equillium, Er-Kim, EspeRare Foundation, Estee Lauder, eTheRNA immunotherapies, Etienna Bio, Eton Pharmaceuticals, Eurofins Scientific, European Wellness Biomedical Group, EVA Pharma, Eve & Co, Evolve BioSystems, Evommune, Evotec, Ewopharma, ExCEEd Orphan, Excelra, Exicure, Fagron, Felix Biotechnology, Fesarius Therapeutics, FibroBiologics, Fission Labs LATAM, Flowerkist, Foamix Pharmaceuticals, Fosun Pharmaceutical, Fresh Tracks Therapeutics, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Galapagos, Galderma, Galenica, Geisel School of Medicine at Dartmouth, Gene Biotherapeutics, Genentech, George Washington University, Gilead Sciences, Ginkgo BioWorks, Givaudan, GL Brands, Glenmark Pharmaceuticals, GPC Systems, Grunenthal, GSK, Guangzhou Xiangxue Pharmaceutical, Hairmore Group, Hangzhou Zhongmei Huadong Pharmaceutical, Happify Health, Harvard Medical School, Hawkeye Therapeutics, Healiant, Helsinn Healthcare, Heumann Pharma Generics, High Beauty, Hill Dermaceuticals, Histogen, HitGen, Hope Medicine, Hoth Therapeutics, Houston Methodist Research Institute, HTDK Group, Huapont Pharma, Hume Supernatural, Huons, Hyloris Pharmaceuticals, Hyphens, Icahn School of Medicine at Mount Sinai, Ice + Jam, Ichnos Sciences, IDEAYA Biosciences, Imbed Bio, IME Medical Electrospinning, IMIDomics, Immunomic Therapeutics, Immuthera, Incannex Healthcare, Incyte, Induce Biologics, InfectoPharm, Infinimmune, Innate Biologics, Innosuisse, Innovate UK, Innovative Cellular Therapeutics, Innovent Biologics, Innovize, Inova Diagnostics, Intas Pharmaceuticals, Integra LifeSciences, International Hyperhidrosis Society, Intralytix, Ionis Pharmaceuticals, IQVIA, Isoprene Pharmaceuticals, Jackson Laboratory, James Cook University, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Janssen Therapeutics, Japan Tobacco, JCR Pharmaceuticals, Jiangsu Hengrui Medicine, Jiangsu QYuns Therapeutics, Joerns Healthcare, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, Journey Medical, Juntendo University, Jupiter Wellness, Juyou Biotechnology, JW Pharmaceutical, Kaken Pharmaceutical, Kaleido Biosciences, Kane Biotech, Kashiv BioSciences, KBI BioPharma, Keck School of Medicine of USC, Kent Imaging, Keraderm, Kerecis, KilgourMD, King's College Hospital, Kiniksa Pharmaceuticals, KiOmed Pharma, KNOW Bio, Komodo Health, Kubota Vision, Kuria Therapeutics, Kyocera, Kyowa Hakko Kirin, L'Oreal, Lannett, Laser Lab Corp, Leman SKL SA, Leon-nanodrugs, LEO Pharma, LGC, LifeMax Laboratories, Ligand Pharmaceuticals, Lighthouse Strategies, Lipidor, LipoTrue, Loreal, Louis Widmer, Lubrizol, Lupin, Lygos, Lysando, Mabwell Bioscience, MagnaPharm Group, MainPointe, Mallinckrodt Pharmaceuticals, Mamba Instruments, Maruho, Massachusetts General Hospital, MatriSys Bioscience, Max-Planck, Mayne Pharma, Mayo Clinic, MC2 Therapeutics, McMaster University, Meabco, Medimetriks, MediPharm Labs, MediWound, Medline Industries, MedPharm, MedShape, Medshift, Meiji Seika, MEME, Menlo Therapeutics, Merakris Therapeutics, Merck and Co, Merck KGaA, Merz, Mesoblast, Metalabs, Metrion Biosciences, Michal Morrison, Michelson Diagnostic, Micreos, Microbio Shanghai, MiMedx, MiNDERA, miraDry, Miravo Healthcare, Mitsubishi Tanabe Pharma, Moberg Pharma, MolecuLight, Molnlycke Health Care, Momenta Pharmaceuticals, Monash University, MoonLake Immunotherapeutics, MorphoSys, Moss Genomics, MT.DERM, MTF Biologics, Mundipharma, MyBiotics Pharma, Mylan Pharmaceuticals, N1 Life, Nabriva Therapeutics, NanoVibronix, National Eczema Association, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, National Psoriasis Foundation, National Research Council Canada, National Research Council of Canada, National Science Foundation, Nationwide Laboratory Services, Nektar Therapeutics, New York University School of Medicine, NEXGEL, Nielsen BioSciences, Nipro Corporation, Nogra Pharma, Nordic Pharma Group, North Carolina State University, Northwestern University, NovaBay Pharmaceuticals, Novan, Novan Therapeutics, Novartis, Novelty Nobility, Novo Nordisk, Now Biopharma, Nuevolution, Nuo Therapeutics, Nuvothera, Oakrum Pharma, Oklahoma Medical Research Foundation, Olaregen Therapeutix, OliX Pharmaceuticals, Oncodesign, Oneness Biotech, OptiBiotix, Or-Genix Therapeutics, Organogenesis, Organ Technologies, ORIG3N, Orphan Europe, Orpharm, Otsuka, Ovation Science, OWC Pharmaceutical Research, Paladin Labs, Palisade Bio, Palvella Therapeutics, Paradigm Therapeutics, Paratek Pharmaceuticals, Patagonia Pharmaceuticals, PathogenDx, Patient-Centered Outcomes Research Institute, PCG Clinical Services, PCI Pharma Services, Pediatric Dermatology Research Alliance, Pediatrix Therapeutics, PellePharm, Pelle Ventures, Pelthos Therapeutics, Perrigo, Pfizer, PharmaResearch Products, Pharming Group, Phosphagenics, Pierre Fabre, Pierre Fabre Dermatologie, Pint Pharma, Piqur Therapeutics, Pixie Dust Technologies, Popit, Portola Pharmaceuticals, Precisio Biotix Therapeutics, Premier Inc, Prescient Surgical, Pressure BioSciences, Prime Therapeutics, Priovant Therapeutics, Promius Pharma, Promore Pharma, Proscia, Protagen, Protagonist Therapeutics, Proteic Bioscience, Proya Cosmetics, Pura Naturals, Purdue Pharma, Purnovate, Pyramid Biosciences, Queensland University of Technology, Quest Pharmaceutical Services, Quoin Pharmaceuticals, Rational Surgical Solutions, Realm Therapeutics, Recludix Pharma, Regenerative Biologics, Regenerative Medicine of Latin America, Regenity Biosciences, Regranion, Relation Therapeutics, ReLeaf Europe, Relife, Renovacare, Repertoire Immune Medicines, Replicel Life Sciences, Repurpose.AI, Resilia Pharmaceuticals, Restorix Health, Revance Therapeutics, Revision Skincare, RIKEN Yokohama Institute Omics Science Center, Rochal Industries, Roche, Rodan and Fields, ROi (Resource Optimization & Innovation), Roivant Sciences, Rubedo Life Sciences, RVL Pharmaceuticals, Samsung Bioepis, Samsung Biologics, Samumed, Sandoz, Sanmina, Sanofi, Sanpellegrino Cosmetics, Sanuwave Health, SastoMed, Sato Pharmaceutical, SciBase, Science 37, Sciton, Scohia Pharma, Searchlight Pharma, Second Genome, Sensus Healthcare, SenzaGen, Seqirus, Sequence Bio, Sequential Skin, SerenaGroup, Shanghai Haohai Biological Technology, Shenzhen Beimei Pharmaceuticals, SHL Medical, Signum Biosciences, Simcere Pharmaceuticals, Simris Biomimetics, Sinclair Pharmaceuticals, Sinovant Sciences, Sirenas, Sirona Biochem, Skin and Cancer Institute, SkinBiotix, SkinSciPac, Skinvisible, Smith & Nephew, Societal CDMO, SoftWave Tissue Regeneration Technologies, Sofwave Medical, Sol-Gel, Soliton, Sonoma Pharmaceuticals, Sosei Heptares, Southwest Transplant Alliance, StemCell Systems, Stratpharma, Sumitomo Chemical Company, Sun Pharmaceutical, SutroVax, Suzhou Connect Biopharmaceuticals, Swiss Institute of Allergy and Asthma Research, Taiho, Takeda Pharmaceutical, Tauriga Sciences, Technion Research and Development Foundation, TekCyte, Telemedicine Solutions, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, TheraVida, Thomas Jefferson University, Thought Leadership & Innovation Foundation, Timber Pharmaceuticals, Tissue Analytics, Tissue Regenix, Tohoku University, Torii Pharmaceutical, Triage Technologies, Turn Therapeutics, TWi Biotechnology, Tyris Therapeutics, uBiome, UMass Chan Medical School, UNION Therapeutics, University Gottingen, University of Alabama at Birmingham, University of Barcelona, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Los Angeles, University of California San Francisco, University of Cincinnati, University of Colorado, University of Colorado Denver, University of Dundee, University of Manchester, University of Maryland Baltimore, University of Massachusetts, University of New Mexico, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of South Australia, University of Virginia, University of Washington, University of Wisconsin, US Army, US Army Medical Research and Material Command, Valeant Pharmaceuticals, ValenzaBio, Vanda Pharmaceuticals, Vanderbilt University, Vasomune Therapeutics, Vaxcyte, Venturis Therapeutics, Vericel, Verily, Verrica Pharmaceuticals, Veterans Medical Distributors, ViaDerma, Vial, Victoria University, Vifor Pharma, Vipergen, VisionQuest Biomedical, Visualant, VisualDx, Vitro Biopharma, Vitruvias Therapeutics, Vizient, Voronoi, Wearifi, Weill Cornell Medical College, Windward Bio, Winhealth Pharma Group, Wistar Institute, Worcester Polytechnic Institute (WPI), Worldwide Clinical Trials, WuXi Biologics, X-chem, Xbiome, Xcede Technologies, Xycrobe Therapeutics, Xylyx Bio, Yale School of Medicine, YOFOTO (China) Health Industry, ZappRx, Zenoaq, Zentiva, Zenyaku Kogyo, Zhittya Genesis Medicine, Zuellig Pharma China, Zymeworks

About Current Partnering

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.

---

Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.

---

Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

• Company press releases and announcements
• SEC filings and equivalent regulatory disclosures
• Company and investor presentations
• Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.

---

Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

• Licensing and co-development
• Research and collaborative R&D
• Manufacturing, supply, and distribution
• Commercialisation and co-promotion
• Equity investments, joint ventures, and asset transactions
• Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.

---

Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

• Financial terms — including upfront payments, milestones, and royalties
• Rights allocation — development, manufacturing, and commercialization responsibilities
• Deal structure — exclusivity, territorial scope, and agreement type
• Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

• Therapy area and technology type
• Stage of development
• Asset type and deal components
• Geographic scope and exclusivity
• Source documentation, including press releases and SEC filings

---

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.

---

Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

• How financial mechanisms are defined and triggered
• How responsibilities are operationalised between parties
• How flexibility, risk, and control are allocated within agreements

---

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:

• Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
• Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
• Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight

Common use cases include:

• Benchmarking comparable transactions
• Supporting valuation and deal structuring
• Preparing for negotiations
• Evaluating potential partners
• Informing internal strategy with real-world evidence

---

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.